|
| 应用凝血酶抑制剂治疗急性缺血性脑卒中的卫生技术评估 |
| Health technology evaluation of using thrombin inhibitors for the treatment of acute ischemic stroke |
| 投稿时间：2024-11-11 修订日期：2024-11-11 |
| DOI： |
| 中文关键词: 阿加曲班注射液 急性缺血性脑卒中 卫生技术评估 |
| 英文关键词: Agatroban Injection Acute ischemic stroke Health Technology Assessment. |
| 基金项目:河南省医学科技攻关计划项目(LHGJ20230402),河南省科技厅科技攻关项目 (202102310172) |
|
| 摘要点击次数: 67 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：应用快速卫生技术评估阿加曲班注射液(凝血酶抑制剂)治疗急性缺血性脑卒中的多效性,为临床治疗方案提供循证参考。方法：计算机检索检索中国知网、万方、维普、生物医学中文数据库和PubMed、Embase、Web of Science、Cochrane Library英文医学数据库及相关卫生技术评估网站,搜集阿加曲班治疗急性缺血性脑卒中的系统评价与Meta分析和药物经济学研究,由两名研究人员独立筛选文献、提取资料并评价纳入研究的质量,对结果进行总结评估。结果：共纳入文献12篇,系统评价和Meta分析8篇,药物经济学研究4篇。有效性分析表明,阿加曲班注射液的使用可提高整体临床有效率,也可以改善神经功能缺损评分和日常生活活动评分。安全性分析表明,使用阿加曲班注射液不会增加出血风险,安全性相对较高。经济性分析表明,分别与降纤酶、静脉溶栓、手术的成本-效果分析相比,阿加曲班在治疗中经济性最高,与尤瑞克林的成本-效用分析相比,联合使用阿加曲班治疗方案具有经济学优势。结论：阿加曲班注射液治疗急性缺血性脑卒中疗效,安全性及经济学好,具有优势。 |
| 英文摘要: |
| Objective：Applying rapid health technology to evaluate the pleiotropy of Agatroban injection (thrombin inhibitor) in the treatment of acute ischemic stroke, providing evidence-based reference for clinical treatment plans. Method：Computer search and retrieval of China National Knowledge Infrastructure, Wanfang, VIP, biomedical Chinese databases, PubMed, Embase, Web of Science, Cochrane Library English medical databases, and related health technology evaluation websites were conducted to collect systematic evaluations, meta-analyses, and pharmacoeconomic studies of Agatroban in the treatment of acute ischemic stroke. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included studies, Summarize and evaluate the results. Result：A total of 12 articles were included, including 8 for systematic evaluation and meta-analysis, and 4 for pharmacoeconomic research. Validity analysis shows that the use of Agatroban injection can improve overall clinical efficacy, as well as improve neurological deficits and daily living activity scores. Safety analysis shows that the use of Agatroban injection does not increase the risk of bleeding, and its safety is relatively high. Economic analysis shows that compared to cost-effectiveness analysis of defibrase, intravenous thrombolysis, and surgery, Agatroban has the highest economic efficiency in treatment. Compared with cost-effectiveness analysis of Urinary Kallidinogenase, the combined use of Agatroban treatment has economic advantages.Conclusion: Agatroban injection is effective, safe, and cost-effective in the treatment of acute ischemic stroke, and has advantages. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|